Characteristics and Outcome of FLT3-ITD-Positive Pediatric Acute Myeloid Leukemia—Experience of Polish Pediatric Leukemia and Lymphoma Study Group from 2005 to 2022
Authors:
- Małgorzata CzogałaMCMałgorzata Czogała
- Wojciech CzogałaWCWojciech Czogała
- Katarzyna Pawińska-WąsikowskaKPKatarzyna Pawińska-Wąsikowska
- Teofila KsiążekTKTeofila Książek
- Karolina Bukowska-StrakovaKBKarolina Bukowska-Strakova
- Barbara Sikorska-FicBSBarbara Sikorska-Fic
- Paweł ŁagunaPŁPaweł Łaguna
- Anna FałkowskaAFAnna Fałkowska
- Katarzyna DrabkoKDKatarzyna Drabko
- Katarzyna Muszyńska-RosłanKMKatarzyna Muszyńska-Rosłan
- Maryna Krawczuk-RybakMKMaryna Krawczuk-Rybak
- Marta KozłowskaMKMarta Kozłowska
Open Access
Abstract
Background: The FMS-like tyrosine kinase 3 (FLT3) gene mutated in 10–15% of pediatric acute myeloid leukemia (AML) is associated with an inferior outcome. The aim of the study was to analyze the outcome and characteristics of FLT3-ITD-positive pediatric AML. Methods: We retrospectively analyzed the nationwide pediatric AML database from between 2005 and 2022. FLT3-ITD was found in 54/497 (10.7%) patients with available analysis. Three consecutive treatment protocols were used (AML-BFM 2004 Interim, AML-BFM 2012 Registry, AML-BFM 2019 recommendations). Results: Probabilities of 5-year overall (OS), event-free (EFS) and relapse-free survival were significantly lower in the FLT3-ITD-positive patients compared to FLT3-ITD-negative (0.54 vs. 0.71, p = 0.041; 0.36 vs. 0.59, p = 0.0004; 0.47 vs. 0.70, p = 0.0029, accordingly). An improvement in the outcome was found in the analyzed period of time, with a trend of better survival in patients treated under the AML-BFM 2012 and AML-BFM 2019 protocols compared to the AML-BFM 2004 protocol (5-year EFS 0.52 vs. 0.27, p = 0.069). There was a trend of improved outcomes in patients treated with FLT3 inhibitors (n = 9, 2-year EFS 0.67 vs. 0.33, p = 0.053) and those who received stem cell transplantation (SCT) (n = 26; 5-year EFS 0.70 vs. 0.27, p = 0.059). The co-occurrence of the WT1 mutation had a dismal impact on the prognosis (5-year EFS 0.23 vs. 0.69, p = 0.002), while the NPM1 mutation improved survival (5-year OS 1.0 vs. 0.44, p = 0.036). Conclusions: It seems that SCT and FLT3 inhibitors have a beneficial impact on the prognosis. Additional genetic alterations, like the WT1 and NPM1 mutations, significantly influence the outcome.Keywords
This publication has 30 references indexed in Scilit:
- Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemiaPediatric Blood & Cancer, 2015
- NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG reportBlood, 2014
- Phase I Pharmacokinetic and Pharmacodynamic Study of the Multikinase Inhibitor Sorafenib in Combination With Clofarabine and Cytarabine in Pediatric Relapsed/Refractory LeukemiaJournal of Clinical Oncology, 2011
- Structural and Functional Alterations of FLT3 in Acute Myeloid LeukemiaClinical Cancer Research, 2009
- Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemiaBlood, 2009
- Clinical implications of FLT3 mutations in pediatric AMLBlood, 2006
- The Structural Basis for Autoinhibition of FLT3 by the Juxtamembrane DomainMolecular Cell, 2004
- FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceBlood, 2003
- Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosisBlood, 2002
- STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.Proceedings of the National Academy of Sciences, 1994